B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

METTL14

MOLECULAR TARGET

methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit

UniProt: Q9HCE5NCBI Gene: 577212 compounds

METTL14 (methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit) is targeted by 2 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting METTL14

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Luteolin 5,7,3',4'-tetrahydroxy-flavone,0.691
2Quercetin0.691

About METTL14 as a Drug Target

METTL14 (methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 2 compounds with documented METTL14 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

METTL14 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.